Anti-CD20 antibody (mAb) represents an effective strategy for the treatment of B cell
malignancies, possibly involving complement activity, antibody-dependent cellular …

Anti-CD20 monoclonal antibodies (mAbs) represent an effective treatment for a number of B
cell malignancies and autoimmune disorders. Glycoengineering of anti-CD20mAb may …

Anti-CD20 Ab therapy has proven successful for treating B cell malignancies and a number
of autoimmune diseases. However, how anti-CD20 Abs operate in vivo to mediate B cell …

Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and
autoimmune disease. However, the cellular and molecular pathways for B cell depletion …

Monoclonal antibodies (mAbs) can destroy tumors by recruiting effectors such as myeloid
cells, or targeting immunomodulatory receptors to promote cytotoxic T cell responses. Here …

CD22 is a cell surface glycoprotein restricted to normal and malignant B‐cells and is the
target of several anti‐CD22 antibody‐based cancer therapies. For therapeutic antibody …

Despite the demonstrated clinical efficacy of CD20 monoclonal antibody (mAb) for
lymphoma therapy, the in vivo mechanisms of tumor depletion remain controversial and …

CD19 is among the most relevant targets in cancer immunotherapy. However, its
extracellular domain (ECD) is prone to aggregation and misfolding, representing a major …

Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …

Abstract Anti-CD19-CAR-T cells are a successful clinical immunotherapy for B cell
lymphomas, although some lymphomas can escape attack by downregulating surface CD19 …